You just read:

U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Sep 30, 2019, 08:30 ET